rasagiline 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
monoamine oxydase (MAO)-inhibitors type B	3521	136236-51-6

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: TVP-1022 rasagiline hydrochloride rasagiline azilect (R)-(+)-Rasagiline rasagiline mesylate TV-1030 rasagiline mesilate	Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of rasagiline tablets on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of rasagiline tablets. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction. Molecular weight: 171.24 Formula: C12H13N CLOGP: 2.34 LIPINSKI: 0 HAC: 1 HDO: 1 TPSA: 12.03 ALOGS: -3.84 ROTB: 2 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

TVP-1022
rasagiline hydrochloride
rasagiline
azilect
(R)-(+)-Rasagiline
rasagiline mesylate
TV-1030
rasagiline mesilate

Rasagiline is a selective, irreversible MAO-B inhibitor indicated for the treatment of idiopathic Parkinson's disease. The results of a clinical trial designed to examine the effects of rasagiline tablets on blood pressure when it is administered with increasing doses of tyramine indicates the functional selectivity can be incomplete when healthy subjects ingest large amounts of tyramine while receiving recommended doses of rasagiline tablets. The selectivity for inhibiting MAO-B diminishes in a dose-related manner. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum. The elevated dopamine level and subsequent increased dopaminergic activity are likely to mediate rasagiline’s beneficial effects seen in models of dopaminergic motor dysfunction.

Molecular weight: 171.24
Formula: C12H13N
CLOGP: 2.34
LIPINSKI: 0
HAC: 1
HDO: 1
TPSA: 12.03
ALOGS: -3.84
ROTB: 2

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
1	mg	O

ADMET properties:

Property	Value	Reference
BA (Bioavailability)	36 %	Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H

Approvals:

Date	Agency	Company	Orphan
May 16, 2006	FDA	TEVA
March 23, 2018	PMDA	Takeda Pharmaceutical Company Limited

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	222.89	22.18	102	4726	46555	50553741
Dyskinesia	195.64	22.18	80	4748	27781	50572515
Hallucination, visual	189.78	22.18	68	4760	16514	50583782
Serotonin syndrome	124.05	22.18	56	4772	24657	50575639
Fall	113.80	22.18	149	4679	334783	50265513
On and off phenomenon	90.29	22.18	22	4806	1390	50598906
Bradykinesia	76.17	22.18	24	4804	3919	50596377
Delusion	72.88	22.18	30	4798	10539	50589757
Pleurothotonus	66.79	22.18	17	4811	1284	50599012
Drug interaction	63.16	22.18	86	4742	199535	50400761
Freezing phenomenon	60.76	22.18	15	4813	1000	50599296
Tremor	56.66	22.18	62	4766	114841	50485455
Confusional state	52.67	22.18	76	4752	185852	50414444
Gambling disorder	48.72	22.18	13	4815	1181	50599115
Orthostatic hypotension	48.71	22.18	32	4796	29449	50570847
Sudden onset of sleep	48.23	22.18	11	4817	521	50599775
Muscle rigidity	42.18	22.18	20	4808	9809	50590487
Impulse-control disorder	40.60	22.18	10	4818	660	50599636
Compulsive shopping	39.91	22.18	10	4818	708	50599588
Hypersexuality	39.08	22.18	9	4819	445	50599851
Stoma site discharge	38.68	22.18	11	4817	1264	50599032
Labelled drug-drug interaction medication error	35.06	22.18	18	4810	10459	50589837
Coronary artery dissection	34.87	22.18	9	4819	718	50599578
Stoma site erythema	33.05	22.18	9	4819	882	50599414
Altered state of consciousness	31.91	22.18	22	4806	21888	50578408
Psychotic symptom	30.32	22.18	9	4819	1203	50599093
Choking	29.60	22.18	15	4813	8483	50591813
Serum serotonin increased	29.47	22.18	6	4822	165	50600131
Compulsive hoarding	28.79	22.18	5	4823	56	50600240
Agitation	28.36	22.18	30	4798	53354	50546942
Anxiety	28.05	22.18	56	4772	177550	50422746
Stoma site extravasation	27.05	22.18	6	4822	250	50600046
Stoma site hypergranulation	26.33	22.18	6	4822	283	50600013
Dementia	25.53	22.18	17	4811	15980	50584316
Resting tremor	25.38	22.18	7	4821	719	50599577
Cerebral atrophy	24.88	22.18	11	4817	4590	50595706
Fracture	24.74	22.18	17	4811	16816	50583480
Gait disturbance	24.52	22.18	48	4780	149957	50450339
Parkinsonian gait	23.79	22.18	6	4822	436	50599860
Nocturia	23.79	22.18	12	4816	6718	50593578
Sleep talking	23.63	22.18	7	4821	929	50599367
Balance disorder	23.12	22.18	31	4797	70559	50529737
Dystonia	22.29	22.18	14	4814	11912	50588384

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	453.83	24.75	224	7446	44488	29522369
Impulse-control disorder	286.80	24.75	66	7604	1159	29565698
Dyskinesia	247.00	24.75	115	7555	19946	29546911
Hypersexuality	208.33	24.75	52	7618	1304	29565553
Hallucination, visual	178.31	24.75	84	7586	14931	29551926
Fall	155.29	24.75	209	7461	176969	29389888
On and off phenomenon	153.63	24.75	44	7626	1884	29564973
Gambling disorder	153.11	24.75	42	7628	1533	29565324
Freezing phenomenon	124.25	24.75	34	7636	1229	29565628
Orthostatic hypotension	122.27	24.75	75	7595	22554	29544303
Confusional state	121.27	24.75	157	7513	127720	29439137
Dopamine dysregulation syndrome	117.13	24.75	25	7645	304	29566553
Delusion	92.43	24.75	49	7621	11167	29555690
Serotonin syndrome	74.61	24.75	50	7620	17462	29549395
Abnormal behaviour	73.03	24.75	55	7615	23072	29543785
Resting tremor	67.19	24.75	18	7652	599	29566258
Somnolence	63.11	24.75	98	7572	93857	29473000
Dystonia	59.57	24.75	35	7635	9714	29557143
Bradykinesia	59.21	24.75	25	7645	3422	29563435
Muscle rigidity	55.44	24.75	33	7637	9378	29557479
Compulsive shopping	55.00	24.75	14	7656	380	29566477
Tremor	52.59	24.75	79	7591	73459	29493398
Cogwheel rigidity	50.75	24.75	17	7653	1226	29565631
Sudden onset of sleep	50.58	24.75	13	7657	367	29566490
Stereotypy	47.86	24.75	14	7656	645	29566212
Stoma site discharge	47.42	24.75	15	7655	902	29565955
Cognitive disorder	45.25	24.75	42	7628	23457	29543400
Balance disorder	44.85	24.75	51	7619	36119	29530738
Supine hypertension	43.12	24.75	11	7659	301	29566556
Akinesia	42.94	24.75	17	7653	1973	29564884
Marasmus	42.59	24.75	12	7658	483	29566374
Jealous delusion	42.19	24.75	10	7660	200	29566657
Psychomotor hyperactivity	41.22	24.75	26	7644	8187	29558670
Embedded device	40.86	24.75	10	7660	230	29566627
Stoma site erythema	39.66	24.75	12	7658	622	29566235
Hyperkinesia	39.25	24.75	15	7655	1584	29565273
Sleep disorder	38.34	24.75	39	7631	24347	29542510
Oesophageal achalasia	37.64	24.75	10	7660	322	29566535
Anticholinergic syndrome	35.60	24.75	12	7658	882	29565975
Rapid eye movement sleep behaviour disorder	35.55	24.75	8	7662	126	29566731
Mesenteric artery thrombosis	35.34	24.75	10	7660	409	29566448
Dementia	35.18	24.75	27	7643	11631	29555226
Obsessive-compulsive personality disorder	34.50	24.75	8	7662	145	29566712
Gait disturbance	34.03	24.75	65	7605	73284	29493573
Paraphilia	33.60	24.75	7	7663	75	29566782
Device dislocation	32.33	24.75	18	7652	4509	29562348
Agitation	32.28	24.75	52	7618	51252	29515605
Hyperthermia	31.02	24.75	23	7647	9407	29557450
Psychotic disorder	30.99	24.75	32	7638	20322	29546535
Thunderclap headache	30.96	24.75	6	7664	43	29566814
Autonomic nervous system imbalance	30.35	24.75	14	7656	2362	29564495
Therapeutic product effect variable	30.20	24.75	13	7657	1864	29564993
Nocturia	28.87	24.75	21	7649	8341	29558516
Restlessness	28.76	24.75	32	7638	22113	29544744
Blood lactic acid	28.02	24.75	8	7662	338	29566519
Disturbance in attention	27.89	24.75	31	7639	21393	29545464
Fracture	27.50	24.75	18	7652	6035	29560822
Toxicity to various agents	27.04	24.75	6	7664	173655	29393202
Micturition disorder	26.81	24.75	12	7658	1889	29564968
Aggression	26.53	24.75	39	7631	35502	29531355
Binge eating	26.52	24.75	6	7664	97	29566760
Dysphagia	25.86	24.75	49	7621	54877	29511980

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Hallucination	509.26	19.41	245	10358	72543	64415586
Dyskinesia	367.20	19.41	162	10441	39226	64448903
Hallucination, visual	323.90	19.41	134	10469	27700	64460429
Impulse-control disorder	261.24	19.41	59	10544	1529	64486600
On and off phenomenon	219.35	19.41	56	10547	2463	64485666
Fall	215.57	19.41	301	10302	416525	64071604
Orthostatic hypotension	177.70	19.41	105	10498	46633	64441496
Hypersexuality	169.56	19.41	41	10562	1438	64486691
Gambling disorder	154.61	19.41	40	10563	1854	64486275
Serotonin syndrome	153.90	19.41	90	10513	39192	64448937
Freezing phenomenon	152.60	19.41	38	10565	1508	64486621
Delusion	129.70	19.41	62	10541	17952	64470177
Dopamine dysregulation syndrome	124.90	19.41	26	10577	453	64487676
Confusional state	121.83	19.41	180	10423	260964	64227165
Bradykinesia	109.32	19.41	41	10562	6519	64481610
Resting tremor	92.21	19.41	25	10578	1389	64486740
Muscle rigidity	90.14	19.41	48	10555	17425	64470704
Dystonia	86.69	19.41	48	10555	18817	64469312
Tremor	86.64	19.41	114	10489	148116	64340013
Sudden onset of sleep	75.75	19.41	18	10585	585	64487544
Stoma site discharge	61.66	19.41	19	10584	1663	64486466
Akinesia	61.51	19.41	22	10581	3057	64485072
Compulsive shopping	61.43	19.41	16	10587	761	64487368
Nocturia	61.35	19.41	32	10571	11133	64476996
Jealous delusion	57.32	19.41	12	10591	215	64487914
Abnormal behaviour	54.97	19.41	45	10558	33577	64454552
Rapid eye movement sleep behaviour disorder	52.46	19.41	12	10591	329	64487800
Dementia	52.27	19.41	36	10567	20730	64467399
Cogwheel rigidity	51.82	19.41	19	10584	2834	64485295
Supine hypertension	51.78	19.41	12	10591	349	64487780
Agitation	51.62	19.41	68	10535	88299	64399830
Drug interaction	51.38	19.41	153	10450	361930	64126199
Balance disorder	51.23	19.41	66	10537	83860	64404269
Stereotypy	50.78	19.41	14	10589	828	64487301
Marasmus	50.36	19.41	14	10589	854	64487275
Autonomic nervous system imbalance	48.35	19.41	20	10583	4112	64484017
Hyperthermia	46.47	19.41	30	10573	15520	64472609
Hyperkinesia	46.40	19.41	17	10586	2529	64485600
Psychotic disorder	45.75	19.41	41	10562	34537	64453592
Disturbance in attention	45.29	19.41	44	10559	41030	64447099
Pleurothotonus	44.30	19.41	16	10587	2286	64485843
Somnolence	44.22	19.41	101	10502	203544	64284585
Mesenteric artery thrombosis	42.01	19.41	11	10592	534	64487595
Gait disturbance	41.45	19.41	89	10514	172066	64316063
Stoma site erythema	41.24	19.41	13	10590	1226	64486903
Choking	40.84	19.41	24	10579	10514	64477615
Anxiety	40.17	19.41	97	10506	202552	64285577
Sleep talking	39.48	19.41	12	10591	1003	64487126
Obsessive-compulsive personality disorder	39.43	19.41	8	10595	122	64488007
Fracture	39.11	19.41	29	10574	18726	64469403
Paraphilia	38.41	19.41	7	10596	58	64488071
Compulsive hoarding	37.60	19.41	7	10596	66	64488063
Oesophageal achalasia	34.91	19.41	10	10593	680	64487449
Micturition urgency	33.48	19.41	21	10582	10338	64477791
Dysphagia	32.61	19.41	61	10542	106751	64381378
Impulsive behaviour	31.53	19.41	13	10590	2650	64485479
Abnormal dreams	30.99	19.41	20	10583	10336	64477793
Aggression	30.80	19.41	38	10565	46194	64441935
Therapeutic product effect variable	30.05	19.41	11	10592	1633	64486496
Altered state of consciousness	29.96	19.41	34	10569	37868	64450261
Neuroleptic malignant syndrome	29.87	19.41	28	10575	24968	64463161
Device dislocation	29.78	19.41	26	10577	21152	64466977
Speech disorder	29.39	19.41	38	10565	48403	64439726
Psychomotor hyperactivity	29.36	19.41	22	10581	14429	64473700
Middle insomnia	29.32	19.41	21	10582	12856	64475273
Blood lactic acid	29.32	19.41	8	10595	455	64487674
Hyperpyrexia	29.18	19.41	15	10588	5062	64483067
Parkinsonian gait	28.64	19.41	9	10594	840	64487289
Presyncope	28.63	19.41	32	10571	35057	64453072
Syncope	28.62	19.41	73	10530	157562	64330567
Cognitive disorder	28.52	19.41	40	10563	55047	64433082
Anticholinergic syndrome	28.15	19.41	12	10591	2657	64485472
Coronary artery dissection	28.03	19.41	9	10594	901	64487228
Nightmare	27.98	19.41	25	10578	20968	64467161
Toxicity to various agents	27.03	19.41	13	10590	363500	64124629
Obsessive-compulsive disorder	27.01	19.41	14	10589	4804	64483325
Disorientation	26.65	19.41	39	10564	55789	64432340
Pneumonia aspiration	26.28	19.41	40	10563	59231	64428898
Micturition disorder	26.25	19.41	12	10591	3136	64484993
Gastrointestinal motility disorder	26.06	19.41	14	10589	5165	64482964
Sleep attacks	25.77	19.41	6	10597	178	64487951
Drooling	25.71	19.41	14	10589	5305	64482824
Sleep disorder	24.66	19.41	39	10564	59670	64428459
Thunderclap headache	24.55	19.41	6	10597	220	64487909
Hip fracture	24.34	19.41	26	10577	27073	64461056
Intermittent claudication	23.46	19.41	11	10592	3043	64485086
Serum serotonin increased	23.31	19.41	6	10597	272	64487857
Prescribed underdose	23.11	19.41	21	10582	17994	64470135
Insomnia	22.85	19.41	78	10525	197758	64290371
Diarrhoea	22.43	19.41	54	10549	722650	63765479
Device occlusion	22.19	19.41	16	10587	9897	64478232
Compulsions	22.01	19.41	6	10597	340	64487789
Delirium	21.71	19.41	40	10563	69154	64418975
Off label use	21.48	19.41	45	10558	632761	63855368
Reduced facial expression	20.64	19.41	9	10594	2104	64486025
Psychotic symptom	20.54	19.41	9	10594	2129	64486000
Poor quality sleep	20.32	19.41	20	10583	18931	64469198
Death	20.17	19.41	142	10461	482563	64005566
Underdose	20.12	19.41	23	10580	25806	64462323
Hyperhidrosis	19.78	19.41	55	10548	124865	64363264
Anosmia	19.63	19.41	11	10592	4406	64483723
Parkinsonism hyperpyrexia syndrome	19.46	19.41	5	10598	225	64487904

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	N04BD02	NERVOUS SYSTEM ANTI-PARKINSON DRUGS DOPAMINERGIC AGENTS Monoamine oxidase B inhibitors
FDA MoA	N0000000184	Monoamine Oxidase Inhibitors
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D008996	Monoamine Oxidase Inhibitors
MeSH PA	D018696	Neuroprotective Agents
MeSH PA	D020011	Protective Agents
FDA EPC	N0000175744	Monoamine Oxidase Inhibitor
CHEBI has role	CHEBI:38623	monoamine oxidase inhibitors
CHEBI has role	CHEBI:63726	neuroprotective agents

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Parkinson's disease	indication	49049000	DOID:14330
Dyskinesia	contraindication	9748009
Bipolar disorder	contraindication	13746004	DOID:3312
Orthostatic hypotension	contraindication	28651003
Hypertensive disorder	contraindication	38341003	DOID:10763
Epilepsy	contraindication	84757009	DOID:1826
Disease of liver	contraindication	235856003	DOID:409
Pheochromocytoma	contraindication	302835009
Malignant melanoma	contraindication	372244006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	7.54	Basic

Orange Book patent data (new drug applications)

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 0.5MG BASE	AZILECT	TEVA	N021641	May 16, 2006	RX	TABLET	ORAL	7815942	Aug. 27, 2027	TREATMENT OF PARKINSONS DISEASE
EQ 1MG BASE	AZILECT	TEVA	N021641	May 16, 2006	RX	TABLET	ORAL	7815942	Aug. 27, 2027	TREATMENT OF PARKINSONS DISEASE

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Amine oxidase [flavin-containing] B	Enzyme	P27338	AOFB_HUMAN	INHIBITOR	Ki	6.15	CHEMBL	CHEMBL
Acetylcholinesterase	Enzyme	P22303	ACES_HUMAN		IC50	7.72	CHEMBL
5-hydroxytryptamine receptor 6	GPCR	P50406	5HT6R_HUMAN		Ki	8.85	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme	P21397	AOFA_HUMAN		Ki	5.01	CHEMBL
Cholinesterase	Enzyme	P06276	CHLE_HUMAN		IC50	5.32	CHEMBL
Amine oxidase [flavin-containing] B	Enzyme		AOFB_RAT		IC50	8.36	CHEMBL
Amine oxidase [flavin-containing] A	Enzyme		AOFA_RAT		IC50	6.39	CHEMBL

External reference:

ID	Source
4025261	VUID
N0000179514	NUI
D02562	KEGG_DRUG
136236-50-5	SECONDARY_CAS_RN
161735-79-1	SECONDARY_CAS_RN
4025261	VANDF
4025262	VANDF
C0525678	UMLSCUI
CHEBI:63620	CHEBI
RAU	PDB_CHEM_ID
CHEMBL887	ChEMBL_ID
DB01367	DRUGBANK_ID
CHEMBL1201142	ChEMBL_ID
CHEMBL1235738	ChEMBL_ID
3052776	PUBCHEM_CID
7151	INN_ID
C031967	MESH_SUPPLEMENTAL_RECORD_UI
6641	IUPHAR_LIGAND_ID
003N66TS6T	UNII
134748	RXNORM
162358	MMSL
20417	MMSL
70623	MMSL
d05612	MMSL
010775	NDDF
010776	NDDF
418734001	SNOMEDCT_US
419010007	SNOMEDCT_US
734664007	SNOMEDCT_US

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3060	TABLET	0.50 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3060	TABLET	0.50 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3061	TABLET	1 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	0093-3061	TABLET	1 mg	ORAL	NDA authorized generic	29 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1270	TABLET	0.50 mg	ORAL	ANDA	30 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1270	TABLET	0.50 mg	ORAL	ANDA	30 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1271	TABLET	1 mg	ORAL	ANDA	30 sections
Rasagiline Mesylate	HUMAN PRESCRIPTION DRUG LABEL	1	0378-1271	TABLET	1 mg	ORAL	ANDA	30 sections
Rasagiline	Human Prescription Drug Label	1	16714-770	TABLET	0.50 mg	ORAL	ANDA	29 sections
Rasagiline	Human Prescription Drug Label	1	16714-771	TABLET	1 mg	ORAL	ANDA	29 sections
Rasagiline Mesylate	Human Prescription Drug Label	1	23155-746	TABLET	0.50 mg	ORAL	ANDA	29 sections
Rasagiline Mesylate	Human Prescription Drug Label	1	23155-747	TABLET	1 mg	ORAL	ANDA	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	42291-779	TABLET	0.50 mg	ORAL	NDA authorized generic	29 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	42291-780	TABLET	1 mg	ORAL	NDA authorized generic	29 sections
RASAGILINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-220	TABLET	0.50 mg	ORAL	ANDA	29 sections
RASAGILINE	HUMAN PRESCRIPTION DRUG LABEL	1	42571-221	TABLET	1 mg	ORAL	ANDA	29 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	43353-015	TABLET	1 mg	ORAL	NDA	30 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	47781-683	TABLET	0.50 mg	ORAL	ANDA	27 sections
Rasagiline	HUMAN PRESCRIPTION DRUG LABEL	1	47781-690	TABLET	1 mg	ORAL	ANDA	27 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	54868-6206	TABLET	1 mg	ORAL	NDA	30 sections
Rasagiline	Human Prescription Drug Label	1	67877-259	TABLET	0.50 mg	ORAL	ANDA	29 sections
Rasagiline	Human Prescription Drug Label	1	67877-260	TABLET	1 mg	ORAL	ANDA	29 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	68546-142	TABLET	0.50 mg	ORAL	NDA	30 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	68546-142	TABLET	0.50 mg	ORAL	NDA	30 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	68546-229	TABLET	1 mg	ORAL	NDA	30 sections
Azilect	HUMAN PRESCRIPTION DRUG LABEL	1	68546-229	TABLET	1 mg	ORAL	NDA	30 sections